Phil Newman

Founder and CEO at Longevity.Technology

Phil Newman delivers the opening remarks at Investing in the Age of Longevity 2024. Introducing the format of the event, which includes a review of “Longevity Next” and “Longevity Now”, Phil gives an overview of the longevity market, including the sector’s past and current financing environment. He also shares Longevity.Technology’s new 10-level classification for analysing the industry, and outlines the trends and investment opportunities that each level entails.

Daniel Ives

CEO at Shift Bioscience

Daniel Ives demonstrates the risk posed by genes that can reverse age and rescue disease. Showcasing the significant increase in experimental power offered by AI cell simulations, he explains how Shift Bioscience uses this type of approach as a path toward safer and simpler cell rejuvenation and disease rescue.

Greg Bailey

Co-founder and Executive Chairman at Juvenescence

Greg Bailey highlights 2025 as an inflection point for both Juvenescence and the industry as a whole and outlines some of his company’s assets as well as the progress made with getting therapeutics into clinical trials. He also looks back at the longevity investment marketplace, and why now is a golden opportunity for investors to get onboard. Summarising Juvenescence’s approach as a mix of business models, Greg shares his view on the potential provided by the consumer marketplace.

Deepankar (Deep) Nayak

CEO at Deep Longevity

Deepankar (Deep) Nayak introduces Deep Longevity’s core product offering, AI-enabled aging clocks which help predict biological age and provide recommendations to improve health. He also outlines the company’s B2B2C business model and its work across different industries, as well as the aging clocks’ availability through APIs or SaaS platforms.

Dr. Emil Kendziorra

Dr. Emil Kendziorra points out how today’s drugs and treatments solely focus on extending health span rather than life span. Making the case for supporting life extension in the future, he introduces Tomorrow Bio’s human cryopreservation approach, an advanced medical procedure that preserves humans after their death. 

Panel Discussion

Kevin Slawin, M.D., Founder and CEO at Eos SENOLYTIX, Greg Bailey, Co-founder and Executive Chairman at Juvenescence, Deepankar (Deep) Nayak, CEO at Deep Longevity, and Dr. Emil Kendziorra, Founder and CEO at Tomorrow Bio, join Phil Newman for a panel discussion at Investing in the Age of Longevity 2024. In their chat, participants answer questions from the audience, and share their views on the envisaged timeline for blockbuster aging therapeutics, as well as realistic overall life span expectations.

Phil Newman

Editor-in-Chief at Longevity.Technology

Phil Newman delivers the opening remarks at Investing in the Age of Longevity 2023. Introducing the format of the event, which includes a review of “Longevity Now” and “Longevity Next”, Phil also briefly reflects on the sector’s investment environment.

Greg Bailey

Co-founder and Executive Chairman at Juvenescence

Greg Bailey joins Phil Newman, Editor-in-Chief at Longevity.Technology, for a chat at Investing in the Age of Longevity 2023. Highlighting the importance of preventitive medicine in the healthcare sector, Greg gives his own estimate of how the longevity space is going to develop over the next five years. He also touches on the industry’s focus on regulation, and gives advice on how private investors can participate in the longevity space. Having explained the Juvenescence model in more detail, Greg also gives an outlook on the company’s product range in 2024.

Petr Sramek

Co-founder, Chairman and Managing/General Partner at LongevityTech.Fund

Petr Sramek explains the attractiveness of the longevity sector for investors, owed to the growth of significant scientific evidence, and how the LongevityTech.Fund taps into this opportunity through its own portfolio of 44 companies. Petr also introduces the Health and Logistics Clinic, an ecosystem company that helps companies move to the clinical environment.

Peter Ward

Co-founder & CEO at Humanity

Peter Ward demonstrates how the Humanity app leverages two key macro market trends: AI and health data. Designed to help people monitor and slow down their rate of aging, the app reportedly has beneficial effects on people’s behaviour change.

Phil Newman

Editor-in-Chief at Longevity.Technology

Phil Newman explores the current state of the longevity space and where it is heading next, and looks at the past and current financing environment across the sector. Defining longevity using four pillars – prevention, diagnostic, renewal, and treatment – Phil explains how the longevity approach differs from the current approach.

David Miles

CEO at AKL Therapeutics

David Miles demonstrates the negative impact of osteoarthritis on healthy aging, and how APPA, a drug under development by AKL, helps address these issues by targeting multiple pathways in osteoarthritis. He also showcases the positive impact that APPA has shown in targeting senescence.

Phil Newman

CEO at First Longevity

Phil Newman delivers the opening remarks at Investing in the Age of Longevity 2022. Reflecting on past developments in the longevity industry, Phil outlines the opportunities provided by the longevity science, technology and commerce going forward.

Aaron Weaver

Principle at Apeiron Investment Group

Aaron gives an overview of investment methodologies and frameworks that can be used for evaluating investment opportunities in the longevity space. Focussing his assessment on biopharmaceutical companies in particular, Aaron goes into detail on key factors such as peer-group analysis, discount-to-cashflow model, revenue expectations, and due diligence.

Petr Sramek

Co-founder, Chairman and Managing/General Partner at Longevitytech.fund

Petr introduces the four pillars of Longevitytech.fund’s investment strategy – timing, diversification, de-risk, support – and also shares a sample of his fund’s investment portfolio.

Alex Blyth

Chief Executive Officer & Founder of LIfT BioSciences

Alex introduces the neutrophil based cell therapy that LIfT BioSciences is developing for the treatment of solid tumours. Demonstrating scientific evidence of the efficacy of Immuno-Modulatory Alpha Neutrophils (IMANs), Alex also explains how the N-LIfT cell therapy platform differentiates from other cell therapies, and how it can be leveraged across other therapy areas.

Fiona Miller

Managing Partner at quadraScope

Fiona takes stock of key developments within the growing longevity space. Highlighting key companies across different industry segments, Fiona also shares a range of early-stage rejuvenation companies that quadraScope is considering to invest in.

Patrick Burgermeister

KIZOO Technology Ventures

Patrick gives an overview of KIZOO Technology Ventures’ investment strategy, with a particular focus on misson-driven investments in early stage companies that open new categories of treatment. Patrick showcases six biotech startups that form part of the company’s key investments: Cellvie, Revel, Cyclarity, LIfT BioSciences, Elastrin, and Mogling Bio.

Stephen Helliwell

Vice President Discovery Biology, Rejuveron Life Sciences AG

Stephen explains Rejuveron Life Sciences’ approach in developing novel therapies for age-related diseases, and expanding these therapies into treatments for an aging population. He also gives a detailed overview of five portfolio companies – endogena, RejuvenateBiomed, senescence therapeutics, telomere therapeutics, and vascular therapeutics – demonstrating their approach to tackling specific aging problems.

Chris Bradley

Co-founder and CEO at Matter Bioworks

Chris stresses the impact of information loss on aging, with a particular focus on the genomic loss of information. Outlining four critical junctures of this information loss process, Chris highlights the four subsidiary companies of Matter Bioworks that address these areas. As an exemplary case, he demonstrates the approach of subsidiary Loki Therapeutics to redirect immune memory in order to combat cancer.

Dani Saurymper

Portfolio Manager at Pacific Asset Management

Dani sets the scene by summarising the global demographic transition and its impact on people’s life span, health span and wealth span. He then explains how Pacific Asset Management seeks to capitalise on these trends by focussing on four investment themes – education and wellbeing, longevity consumer, healthcare, and later-living – and gives examples of portfolio companies in these areas.

Tom Weldon

Founder, Executive Chairman and Acting CEO at Ponce De Leon Health

Tom introduces Rejuvant, a supplement developed by Ponce De Leon Health to decrease biological age in humans. Referencing data from clinical studies to evidence the efficacy of Rejuvant, Tom goes on to outline the product’s marketing roadmap and next funding round.

Peter Ward

Co-founder and CEO at Humanity

Peter introduces Humanity, a consumer app that allows its users to monitor and slow down their rate of aging. Analysing a sample of statistics, Peter also demonstrates the app’s impact on health actions taken by its users.

Richard Faragher

The Geroscience Promise: The Biology of Age-Related Disease and The Potential of Therapeutic Interventions

Janet Lord

The aged immune system – a central driver of ageing

(NB: for reasons of copyright, confidentiality and compliance, some aspects of this deck have been edited to differ from that delivered live at the event.)

Michael Hufford

Prometheus Unbound: From Myth to the Clinical Rea- lity of Organ Regeneration

James Peyer

Cambrian Bio – Creating longevity drugs at scale

Phil Newman, Greg Bailey and James Peyer

Q&A Panel

Dr Geoff Mullan

We love longevity, but my heart’s in healthspan

George Sutherland

Crossing the chasm: priming the market for longevity interventions

Simon Baldry

A Healthy Brain for Life

Nir Barzilai

Targeting Aging with Metformin (TAME): A Concrete Plan to Pave the Way for Targeting Aging

Jim Mellon, James Peyer, Mehmood Khan and Kristen Fortney

Rejuvenating and uniting the industry to target health span and life span

The Opportunity for Investors

The progress being made in extending life- and health-spans represents both a challenge and an opportunity. How can we ensure our investments see us comfortably through an extended life and how can we capitalise on the huge financial possibilities that successful treatments for aging would present? This panel brings together three of the leading investors in the field of Longevity to discuss the opportunities and potential pitfalls.

The Science of Ageing

We are on the cusp of a revolution in our understanding of the causes and consequences of aging. As aging research gathers pace, this panel discussion brings together some of the leading experts in the field of gerontology to discuss the cutting edge scientific work being done to advance the fight against aging.

2019 Highlights

Watch a 2-minute highlights video of the 2019 event.

Jim Mellon

Dr Aubrey de Grey

Rejuvenation Biotechnology: on track to be the biggest industry ever

Declan Doogan

Health in the Age of Longevity

Reason

Gene Therapies to Reverse Immunosenescence and Atherosclerosis

William Baines

Five Alarm Bio

Petr Fedichev

Gero

Yuri Deigin

Youthereum

Sergey Young

7 Signs of Longevity Revolution

SUBSCRIBE